Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Research and Clinical Oncology
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2010

01.06.2010 | Original Paper

Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer

verfasst von: Xu Zhou, Wantao Chen, Yuexing Zhang, Jian Sun, Qing Wang, Youcheng Yu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

An ErbB3-binding protein 1 (Ebp1), was shown to be a potent tumor suppressor in breast and prostate cancer cells. We hypothesized that the inhibitory properties of the Ebp1 gene could be beneficial if ectopically expressed in oral squamous cell carcinoma (OSCC) cells.

Methods

One OSCC cell line Tca8113 was stably transfected with the complete Ebp1 cDNA or the vector control pcDNA3.1. The inhibitory effect was evaluated using in vitro proliferation assay, cell cycle distribution and anchorage-independent growth in soft agar as well as in vivo tumorigenicity.

Results

Stable gene transfer was verified by Western Blot analysis and reverse transcription RT-PCR. Following transfection of Ebp1, a significant reduction in cell proliferation and anchorage-independent growth in soft agar were observed. Ectopic expression of Ebp1 led to a change in cell cycle profile and most importantly, a strong decrease in tumorigenicity of human OSCC cell line in a xenograft mouse model.

Conclusions

Ectopic expression of Ebp1 mediates multiple antitumor activities against OSCC, suggesting a potential of Ebp1-based novel therapy for clinical OSCC treatment.
Literatur
Bernier J, Bentzen SM, Vermorken JB (2009) Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 6:266–277CrossRefPubMed
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMed
Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987CrossRefPubMed
Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97:4227–4232CrossRefPubMed
Hamburger AW (2008) The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia 13:225–233CrossRefPubMed
Horváth BM, Magyar Z, Zhang Y, Hamburger AW, Bakó L, Visser RG, Bachem CW, Bögre L (2006) EBP1 regulates organ size through cell growth and proliferation in plants. EMBO J 25:4909–4920CrossRefPubMed
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed
Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24:2666–2672CrossRefPubMed
Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70–82CrossRefPubMed
Kim MM, Califano JA (2004) Molecular pathology of head-and-neck cancer. Int J Cancer 112:545–553CrossRefPubMed
Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR (2008) Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 14:4284–4291CrossRefPubMed
Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR (2003) Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100:4138–4143CrossRefPubMed
Lessor TJ, Yoo JY, Xia X, Woodford N, Hamburger AW (2000) Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol 183:321–329CrossRefPubMed
Lui VW, Grandis JR (2002) EGFR-mediated cell cycle regulation. Anticancer Res 22:1–11PubMed
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021–3031CrossRefPubMed
Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, Jinawath N, Tsai MH, Chang NW, Lin CF, Lin CC, Hsieh LJ, Wang TL, IeM Shih, Tsai FJ (2009) Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 69:2568–2576CrossRefPubMed
Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15:413–448CrossRefPubMed
Specenier PM, Vermorken JB (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8:375–391CrossRefPubMed
Vermorken JB (2005) Medical treatment in head and neck cancer. Ann Oncol 16(suppl 2):ii258–ii264CrossRefPubMed
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127CrossRefPubMed
Wen Y, Yan DH, Wang B, Spohn B, Ding Y, Shao R, Zou Y, Xie K, Hung MC (2001) p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Res 61:7142–7147PubMed
Xia X, Lessor TJ, Cheng A, Zhang Y, Hamburger AW (2001) Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol 187:209–217CrossRefPubMed
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137CrossRefPubMed
Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, Hamburger AW (2000) Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer 82:683–690CrossRefPubMed
Yu Y, Chen W, Zhang Y, Hamburger A, Pan H, Zhang Z (2007) Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 Binding protein Ebp1 transfer. Int J Cancer 120:1909–1913CrossRefPubMed
Zhang Y, Fondell JD, Wang Q, Xia X, Cheng A, Lu ML, Hamburger AW (2002) Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene 21:5609–5618CrossRefPubMed
Metadaten
Titel
Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer
verfasst von
Xu Zhou
Wantao Chen
Yuexing Zhang
Jian Sun
Qing Wang
Youcheng Yu
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0730-1

Weitere Artikel der Ausgabe 6/2010

Journal of Cancer Research and Clinical Oncology 6/2010 Zur Ausgabe

Original Paper

Transformation potential of bone marrow stromal cells into undifferentiated high-grade pleomorphic sarcoma

Original Paper

Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study

Original Paper

The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens

Original Paper

Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma

Original Paper

Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-κB

Original Paper

Increased expression of cellular retinol-binding protein 1 in laryngeal squamous cell carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise